scholarly journals GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease

2022 ◽  
Vol 146 ◽  
pp. 112582
Author(s):  
Qing-Ao Xiao ◽  
Qian He ◽  
Jun Zeng ◽  
Xuan Xia
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Target ◽  
Metabolic Disorders

Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target

2017 ◽  
Vol 15 (5) ◽  
Author(s):  
Felice Gragnano ◽  
Enrica Golia ◽  
Francesco Natale ◽  
Renatomaria Bianchi ◽  
Ivana Pariggiano ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Von Willebrand Factor ◽  
Therapeutic Target ◽  
Biochemical Marker ◽  
Attractive Therapeutic Target ◽  
Von Willebrand ◽  
Willebrand Factor

scholarly journals The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

2008 ◽  
Vol 153 (6) ◽  
pp. 1105-1119 ◽  
Author(s):  
N S Kirkby ◽  
P W F Hadoke ◽  
A J Bagnall ◽  
D J Webb
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Target ◽  
Great Expectations ◽  
Bleak House ◽  
Endothelin System

scholarly journals Netrin-1 as a novel therapeutic target in cardiovascular disease: to activate or inhibit?

2015 ◽  
Vol 107 (4) ◽  
pp. 410-419 ◽  
Author(s):  
Kerry Layne ◽  
Albert Ferro ◽  
Gabriella Passacquale
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Target ◽  
Novel Therapeutic

VEGF Signaling: A Therapeutic Target for Cardiovascular Disease

2008 ◽  
pp. 301-326 ◽  
Author(s):  
Dhanya Chandrasekharan Rajalakshmi ◽  
Aghila Rani Koippallil Gopalakrishnan ◽  
Chandrasekharan Cheranellore Kartha
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Target ◽  
Vegf Signaling

Burden of chronic conditions among persons with HIV/AIDS and psychiatric comorbidity

2021 ◽  
Vol 19 ◽  
Author(s):  
Sumedha Chhatre ◽  
George Woody ◽  
David S Metzger ◽  
Ravishankar Jayadevappa
Keyword(s):  
Cardiovascular Disease ◽  
Substance Use ◽  
Infectious Diseases ◽  
Metabolic Disorders ◽  
Psychiatric Comorbidity ◽  
Medical Expenditure ◽  
Medical Comorbidity ◽  
Medical Comorbidities ◽  
Persons Living With Hiv ◽  
Intermediate Outcomes

Background: Improved survivorship among persons living with HIV translates into higher risk of medical comorbidities. Objective : We assessed the association between intersection of physical (HIV) and mental health (psychiatric) conditions and intermediate outcomes. Methods: Cross-sectional study of Medical Expenditure Panel Survey (MEPS)-Household Component between 1996 and 2016. We created four groups for persons aged ≥18: (1) HIV + psychiatric comorbidity, (2) HIV, (3) psychiatric comorbidity, and (4) no-HIV/no-psychiatric comorbidity. We compared the burden of medical comorbidities (metabolic disorders, cardiovascular disease, cancers, infectious diseases, pain, and substance use) across groups using chi square tests. We used logistic regression to determine the association between group status and medical comorbidity. Results: Of 218,133,630 (weighted) persons aged ≥18, 0.18% were HIV-positive. Forty-three percent of HIV group and 19% of no-HIV group had psychiatric comorbidities. Half of the HIV+ psychiatric disorder group had at least one medical comorbidity. Compared to the no-HIV/no-psychiatric comorbidity group, the HIV + psychiatric comorbidity group had highest odds of medical comorbidity (OR= 3.69, 95% CI = 2.99, 4.52). Conclusion: Persons presenting with HIV + psychiatric comorbidity had higher odds of medical comorbidities of pain, cancer, cardiovascular disease, substance use, metabolic disorders and infectious diseases, beyond that experienced by persons with HIV infection or psychiatric disorders, independently. Future research will focus on the mediating effects of social determinants and biological factors on outcomes as quality of life, cost and mortality. This will facilitate a shift away from the single-disease framework and compress morbidity of the aging cohort of HIV-infected persons.

scholarly journals Associations of Cardiovascular and All-Cause Mortality with Metabolic Syndrome in Hemodialysis Patients: A Prospective Single-Center Study

Medicina ◽  
2019 ◽  
Vol 55 (10) ◽  
pp. 694
Author(s):  
Zorica Dimitrijevic ◽  
Andriana Jovanovic ◽  
Mina Cvetkovic ◽  
Tamara Vrecic ◽  
Emina Kostic ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Metabolic Disorders ◽  
Cardiometabolic Risk ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Single Center Study ◽  
All Cause Mortality

Background and objectives: Metabolic syndrome (MetS) is a cluster of risk factors, such as abdominal obesity, insulin resistance, dyslipidemia and hypertension, that together increase the risk of cardiovascular disease. Chronic hemodialysis (HD) patients have multiple comorbidities and many metabolic disorders, causing the frequent occurrence of metabolic syndrome. The goal of this study was to assess the prevalence of MetS in HD patients, and its association with all-cause and cardiovascular (CV) mortality. Patients and methods: A total of 138 HD patients were included in this prospective study. We analyzed demographic, anthropometric and biochemical data. Outcome measures were all-cause and CV mortality during the three-year follow-up. Results: MetS was diagnosed in 57.24% of enrolled patients. During the 36 months of follow-up, 33 patients died. MetS patients showed a significantly higher mortality rate than non-MetS (30.4% versus 16.36%, p < 0.001). The association of different MetS components with cardiovascular mortality reached significance when a minimum of three components were present (1.81 (95% confidence interval CI = 1.21–2.33)), with a grouped increase in effect size for subjects with four or five MetS components. Subjects with MetS exhibited nearly twice as high risk for all-cause (hazard ratio HR = 1.99 (95%CI) = 1.42–2.97) and 2.5 times for CV (HR = 2.51 (95%CI) = 1.25–3.83) mortality compared with those without MetS, after adjustment for age, gender, and cardiovascular disease. Conclusions: The study demonstrates that MetS is widespread in HD patients. In future, the focus must be on an active screening approach, and treatment of cardiometabolic risk factors, aiming to reduce mortality.

CD38: A Potential Therapeutic Target in Cardiovascular Disease

2020 ◽  
Author(s):  
Wanyun Zuo ◽  
Na Liu ◽  
Yunhong Zeng ◽  
Yaozhong Liu ◽  
Biao Li ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Target ◽  
Potential Therapeutic Target
Sign in / Sign up

Export Citation Format

Share Document